Compare · DRTS vs MDLN
DRTS vs MDLN
Side-by-side comparison of Alpha Tau Medical Ltd. (DRTS) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRTS and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 53.7x DRTS ($822.9M).
- Over the past year, DRTS is up 204.0% and MDLN is down 18.0% - DRTS leads by 221.9 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 10 for DRTS).
- MDLN has more recent analyst coverage (25 ratings vs 7 for DRTS).
PerformanceDRTS+99.06%MDLN-17.95%
2025-12-17+0.00%2026-06-08
- Company
- Alpha Tau Medical Ltd.
- Medline Inc.
- Price
- $9.52+1.66%
- $33.43-0.51%
- Market cap
- $822.9M
- $44.15B
- 1M return
- +21.29%
- -20.41%
- 1Y return
- +203.99%
- -17.95%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 10
- 20
- Recent ratings
- 7
- 25
DRTS
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Latest DRTS
- Chief Financial Officer Levy Raphi sold $352,115 worth of Ordinary Shares (32,500 units at $10.83), decreasing direct ownership by 18% to 147,680 units (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
- Barclays initiated coverage on Alpha Tau with a new price target
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Alpha Tau to Participate in May Investor Conferences
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)